Abstract:Clinical trials of the PET amyloid imaging agent (18)F-flutemetamol have used visual assessment to classify PET scans as negative or positive for brain amyloid. However, quantification provides additional information about regional and global tracer uptake and may have utility for image assessment over time and across different centers. Using postmortem brain neuritic plaque density data as a truth standard to derive a standardized uptake value ratio (SUVR) threshold, we assessed a fully automated quantification method comparing visual and quantitative scan categorizations. We also compared the histopathology-derived SUVR threshold with one derived from healthy controls. Methods: Data from 345 consenting subjects enrolled in 8 prior clinical trials of (18)F-flutemetamol injection were used. We grouped subjects into 3 cohorts: an autopsy cohort (n = 68) comprising terminally ill patients with postmortem confirmation of brain amyloid status; a test cohort (n = 172) comprising 33 patients with clinically probable Alzheimer disease, 80 patients with mild cognitive impairment, and 59 healthy volunteers; and a healthy cohort of 105 volunteers, used to define a reference range for SUVR. Visual image categorizations for comparison were from a previous study. A fully automated PET-only quantification method was used to compute regional neocortical SUVRs that were combined into a single composite SUVR. An SUVR threshold for classifying scans as positive or negative was derived by ranking the PET scans from the autopsy cohort based on their composite SUVR and comparing data with the standard of truth based on postmortem brain amyloid status for subjects in the autopsy cohort. The derived threshold was used to categorize the 172 scans in the test cohort as negative or positive, and results were compared with categorization using visual assessment. Different reference and composite region definitions were assessed. Threshold levels were also compared with corresponding thresholds derived from the healthy group. Results: Automated quantification (using pons as the reference region) demonstrated 91% sensitivity and 88% specificity and gave 3 false-positive and 4 false-negative scans. All 3 false-positive cases were either borderline-normal by standard of truth or had moderate to heavy cortical diffuse plaque burden. In the test cohort, the concordance between quantitative and visual read categorization ranged from 97.1% to 99.4% depending on the selection of reference and composite regions. The threshold derived from the healthy group was close to the histopathology-derived threshold. Conclusion: Categorization of (18)F-flutemetamol amyloid imaging data using an automated PET-only quantification method showed good agreement with histopathologic classification of neuritic plaque density and a strong concordance with visual read results.

Improved Comparability Between Measurements of Mean Cortical Amyloid Plaque Burden Derived from Different PET Tracers Using Multiple Regions‐of‐interest and Machine Learning

Harmonizing florbetapir and PiB PET measurements of cortical Aβ plaque burden using multiple regions‐of‐interest and machine learning techniques: An alternative to the Centiloid approach

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST

Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads

Comparison of two semi‐quantitative amyloid PET analysis methods with and without MRI in Alzheimer’s Disease Spectrum Disorder

Florbetapir PET Measurements of Amyloid Plaque Deposition Are More Closely Correlated with Cross‐Sectional and Longitudinal Cognitive and Clinical Measurements Using a White Matter Reference Region of Interest

Accuracy and longitudinal consistency of PET/MR attenuation correction in amyloid PET imaging amid software and hardware upgrades

Closer Correlations Between Florbetapir PET Measurements of Amyloid Plaque Burden Using a Cerebral White Matter Reference Region and Alzheimer’s Disease‐related Hypometabolism

Tracer-specific reference tissues selection improves detection of F-18-FDG, F-18-florbetapir, and F-18-flortaucipir PET SUVR changes in Alzheimer's disease

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

P1‐118: QUANTIFICATION OF AMYLOID BURDEN FROM FLORBETAPIR PET WITHOUT USING TARGET AND REFERENCE REGIONS: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH

Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.

Parametric Estimation of Reference Signal Intensity in the Quantification of Amyloid-Beta Deposition: an 18F-AV-45 Study.

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [18F]-APN-1607 Study.

QUANTIFICATION OF AMYLOID BURDEN FROM FLORBETAPIR PET IMAGES WITHOUT USING TARGET AND REFERENCE REGIONS: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH

[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer's disease

A 2.5D Residual U‐Net for Improved Amyloid PET Harmonization Preserving Spatial Information

Impact of Reference Region on Longitudinal Florbetapir PET SUVR Changes from the API ADAD Colombia Trial

P2‐071: comparing cerebral white matter, cerebellar, and pontine reference regions to characterize florbetapir pet measurements of amyloid‐β burden in psen1 e280a mutation carriers and noncarriers from the colombian autosomal dominant alzheimer's disease kindred

IC‐P‐010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOID‐β BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED